Amarin vs Ligand Pharmaceuticals
AMRN and LGND side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMRN and LGND compare
Ligand Pharmaceuticals is the larger company, worth 1.2 times as much as Amarin ($6.2B against $5.0B).
Ligand Pharmaceuticals grew revenue faster over the last twelve months (1.0% versus −22.3% for Amarin).
Ligand Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 20.3% compared with −10.9% at Amarin.
Amarin scores higher on the StockData Score (10 against 6 for Ligand Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMRN | LGND |
|---|---|---|
| Size and price | ||
| Market cap | $5.0B | $6.2B |
| Share price | $11.38 | $308.79 |
| Change, 1 year | −29.8% | 50.2% |
| Change, 5 years | −85.4% | 90.7% |
| Beta (5Y) | 1.54 | 1.30 |
| Employees | 80 | 47 |
| StockData Score | ||
| Total score | 10 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 3 | 3 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 135× |
| P/S | 28.6× | 24.3× (better) |
| P/B | 11.3× | 6.4× (better) |
| EV/EBITDA | – | 113× |
| P/FCF | – | 68.2× |
| FCF yield | – | 1.5% |
| Fair value | $7.00 | $55.48 |
| Margin of safety | −62.5% (better) | −457% |
| Growth | ||
| Revenue growth (TTM) | −22.3% | 1.0% (better) |
| Revenue growth, 5Y average | −19.0% | 10.4% (better) |
| Net income growth (TTM) | – | 5.9% |
| EPS growth (TTM) | – | 18.7% |
| Profitability | ||
| Gross margin | 40.9% | – |
| Operating margin | −18.2% | 10.1% (better) |
| Net margin | −10.9% | 20.3% (better) |
| FCF margin | – | 35.7% |
| Return on equity | −4.2% | 5.4% (better) |
| Return on invested capital | −17.3% | 2.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 1.17 (better) |
| Net debt / EBITDA | – | 11.26 |
| Interest coverage | – | 3.1× |
| Current ratio | 3.50 (better) | 1.22 |
| Altman Z-score | 13.05 (better) | 3.46 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 1.0% | 113% |
| Held by insiders | 7.0% | 2.6% |
| Insider net buying, 12 months | – | −$35.7M |
Go deeper
- AMRN stock overview
- AMRN income statement
- AMRN valuation and score
- LGND stock overview
- LGND income statement
- LGND valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.